ClinicalTrials.gg
CompletedNCT06824428Updated Dec 30, 2025

The Pain Perception Threshold in Attention Deficit Disorder With Hyperactivity

An observational study in Pain Threshold and Attention Deficit Disorder With Hyperactivity (ADHD), sponsored by Sultan 1. Murat State Hospital. Completed at 1 site in Turkey (Türkiye). Open to participants aged 6 Years to 17 Years. Per ClinicalTrials.gov, last updated 2025-12-30.

Sponsored by Sultan 1. Murat State Hospital · Observational

Study type
Observational
Model
Case-control
Time perspective
Cross-sectional
Enrollment
84
Ages
6 Years to 17 Years
Sex
All
01

Study summary

The aim of this study was to evaluate whether the disease subtype affects the presence of chronic pain and pain perception threshold in pediatric patients followed up with the diagnosis of attention deficit and hyperactivity disorder, and to evaluate the factors that may be related to pain perception threshold in disease subtypes.

02

Conditions studied

  • Pain Threshold
  • Attention Deficit Disorder With Hyperactivity (ADHD)
03

In context

Attention Deficit Disorder with Hyperactivity

1,817 studies on the registry are indexed under Attention Deficit Disorder with Hyperactivity; 296 are open to participants now.

This study's enrollment of 84 is below the median of 127 across 329 observational studies indexed under Attention Deficit Disorder with Hyperactivity.

Browse Attention Deficit Disorder with Hyperactivity studies →

Lead sponsor

Sultan 1. Murat State Hospital is the lead sponsor of 7 studies on the registry; 1 is open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
6 Years to 17 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Patients will be selected from among those who apply to Edirne Sultan 1. Murat State Hospital Child and Adolescent Mental Health and Diseases polyclinic.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnosed with attention deficit and hyperactivity disorder according to diagnostic criteria
  • Being between the ages of 6-17
  • Being at a clinically normal mental level

Exclusion criteria

Exclusion Criteria:

  • Having verbal and visual communication problems
  • Having a history of perinatal complications or physical head trauma
  • Having comorbid psychiatric disorders other than oppositional defiant disorder and conduct disorder
  • Known history of chronic physical and neurological disease (such as cerebral palsy, diabetes, epilepsy, diseases, liver and kidney failure)
  • Presence of substance or alcohol use disorder
  • Having a genetic disorder diagnosis
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

05

Study design

Observational model
Case-control
Time perspective
Cross-sectional
Enrollment
84 participants (actual)
Patient registry
No

Groups and cohorts

  • Predominantly Inattentive

    Patients diagnosed with inattentive subtype of attention deficit disorder with hyperactivity according to DSM-5 diagnostic criteria.

    Other: Pain perception threshold

  • Predominantly Hyperactive-Impulsive

    Patients diagnosed with hyperactive-impulsive subtype of attention deficit disorder with hyperactivity according to DSM-5 diagnostic criteria.

    Other: Pain perception threshold

  • Inattentive and Hyperactive-Impulsive Combination

    Patients diagnosed with mix subtype of attention deficit disorder with hyperactivity according to DSM-5 diagnostic criteria.

    Other: Pain perception threshold

Interventions

  • OtherPain perception threshold

    The patients' pressure pain threshold will be evaluated with a manual pressure algometer (Baseline Dolorimtre®).The patients' pain perception thresholds will be measured bilaterally in the midfrontal region, the midpoint of the trapezius muscle, the lateral epicondyle, the midpoint of the web between the 1st and 2nd fingers, the greater trochanter, and the medial crease of the knee.

06

What researchers measure

Primary outcomes

  1. pressure pain threshold

    The pressure pain threshold will be assessed with a manual pressure algometer (Baseline Dolorimtre®). The patients' pain perception thresholds will be measured bilaterally in the midfrontal region, the midpoint of the trapezius muscle, the lateral epicondyle, the midpoint of the web between the 1st and 2nd fingers, the greater trochanter, and the medial crease of the knee. During the measurement, the 1.52 cm2 flat circular probe of the algometer will be placed on the relevant area and the pressure will be increased by 1 kg/second. Patients will be asked to express their pain by saying 'stop' or raising their hands when they feel slight discomfort. The value for each reference area will be obtained by calculating the arithmetic mean of the paired measurements.

    Time frame: Baseline

Secondary outcomes

  1. Presence of chronic pain

    It will be questioned whether there has been continuous pain in any part of the body for at least 3 months.

    Time frame: Baseline

  2. Pain score

    The patients' pain score will be evaluated with the Numerical Rating Scale (NRS). A 10 cm long horizontal straight line will be used in the NRS evaluation. Before the evaluation, the patient will be informed that a value of 0 represents no pain and a value of 10 represents the most severe pain felt to date. Patients will be asked to answer by considering the average of their pain over the last 3 days.

    Time frame: Baseline

  3. Duration of chronic pain

    The duration of pain that has continued for at least 3 months in any part of the body will be questioned.

    Time frame: Baseline

  4. Sociodemographic data of patient

    gender, age, height, weight, age of onset of complaints, duration of medication use, number of siblings, primary caregiver

    Time frame: Baseline

  5. Sociodemographic data of patient's parents

    Age, occupation, education level and psychiatric disease history of mother and father

    Time frame: Baseline

07

Study locations

1 site
  • Sultan 1. Murat State Hospital
    Edirne, 22030, Turkey (Türkiye)
08

References and documents

Individual participant data

Plan to share: Yes — If requested, the data of the study will be shared by the researchers.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Feb 2025 to primary completion in Dec 2025, 10 months.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 7, 2025
First posted
Feb 13, 2025
StartActual
Feb 16, 2025
Primary completionActual
Dec 26, 2025
CompletionActual
Dec 26, 2025
Last update
Dec 30, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 30, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06824428
Lead sponsor
Sultan 1. Murat State Hospital
Responsible party
Alper Mengi (Associate Professor, Sultan 1. Murat State Hospital) — Principal investigator
First posted
Feb 13, 2025
Start date
Feb 16, 2025
Primary completion
Dec 26, 2025
Completion
Dec 26, 2025
Last update
Dec 30, 2025

Study contacts

İbrahim Tiryaki, MD
principal investigator · Sultan 1. Murat State Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion